Inhibrx Biosciences, Inc. (INBX) — 10-Q Filings
All 10-Q filings from Inhibrx Biosciences, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Inhibrx Narrows Q3 Loss, R&D Costs Plummet Post-Spin-Off
— Nov 14, 2025 Risk: medium
Inhibrx Biosciences, Inc. (INBX) reported a net loss of $35.256 million for the three months ended September 30, 2025, an improvement from the $43.864 million n -
Inhibrx Swings to Loss Post-Sanofi Deal, R&D Costs Plummet
— Aug 13, 2025 Risk: medium
Inhibrx Biosciences, Inc. (INBX) reported a net loss of $28.65 million for the three months ended June 30, 2025, a significant decrease from the net income of $ -
Inhibrx Biosciences Files Q1 2025 10-Q
— May 14, 2025 Risk: medium
Inhibrx Biosciences, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Ibex SpinCo, Inc. until January 11, 20 -
Inhibrx Biosciences Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Inhibrx Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its busine -
Inhibrx Biosciences Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
Inhibrx Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business op
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX